Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial

European Urology Focus · Published 2026-07-01 · DOI 10.1016/j.euf.2026.07.006

Authors (3)

Gemma Sheehan-Dare, Sobia Khan, Louise Emmett

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Sheehan-Dare, G., Khan, S., Emmett, L. (2026). Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial. European Urology Focus. https://doi.org/10.1016/j.euf.2026.07.006

Related articles

• BCG at Home: A First-in-kind Trial of Home-based Intravesical Bacillus Calmette-Guérin Delivery for High-risk Non–muscle-invasive Bladder Cancer · European Urology Focus · 2026 · Same journal
• Radioligand Therapy (RLT) in France · European Urology Focus · 2026 · Same journal
• Seeking a Credible Basis for Prostatic Obstruction as the Reversible Cause of Other Lower Urinary Tract Dysfunctions · European Urology Focus · 2026 · Same journal
• Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer · European Urology Focus · 2026 · Same journal
• Early-access Use of Radioligand Therapy in Prostate Cancer · European Urology Focus · 2026 · Same journal
• Genitourinary Injury After Radiation Therapy: Understanding Burden of Disease and Evolving Therapeutic Advancements · European Urology Focus · 2026 · Same journal
• Conceptualizing the “High” Bladder Neck – Anatomic Rabbit Hole or Functional Gold Mine? · European Urology Focus · 2026 · Same journal
• Postvoided Residual/Bladder Emptying: A Mini Review · European Urology Focus · 2026 · Same journal
• Contemporary Prostate Cancer Intraprostatic Imaging Scores: A Practical and Hands-on Guide for Urologists · European Urology Focus · 2026 · Same journal
• Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update · European Urology Focus · 2026 · Same journal